Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREFAcE: PET-PSMA Potentiated by Androgen Blockade in Prostate Cancer Recurrence
NCT04391556Phase 2Completed
- Sponsor
- Centre Léon Bérard
- Start
- Sep 2020
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of degarelix in prostate adenocarcinoma, sponsored by Centre Léon Bérard. Primary endpoint: Comparison of the proportion of patients presenting a positive PET during the initial PSMA-PET and the PSMA-H-PET at Day 14. Started Sep 2020; status: completed.
02
Drugs
degarelix
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04391556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04391556.